PhaseII Study of Neoadjuvant and adjuvant Chemotherapy with Pemetrexed/Carboplatin/Bevacizumab in patients with non-squamouns non Small-cell lung cancer
- Conditions
- on-Squamouns Non-small-cell-lung-cancer
- Registration Number
- JPRN-UMIN000009032
- Lead Sponsor
- Kansai Medical University Hirakata Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
Not provided
>preoperative therapy (1) severe comorbit disease (2) history of hemoptysis, coagulation disorder and thrombosis or receive oral/i.v. hemostatic drug (3) With a clinical bleeding tendency (4) tumor cavitation and invasion to the major vessel (5) Patients of Untreated fracture (Such as compression fractures due to osteoporosis are excluded) or High degree of wound (7)Patients of the merger of infections requiring intravenous administration of anti-viral agents or anti-fungal agents,antibiotics (8) Patients with therapeutic anticoagulopathy (including Aspirin over 325mg/day) (9) Patients with uncontrollable gastrointestinal ulceration (10) Patients with current or previous (within one year) history of gastrointestinal perforation (11) Patients with Symptomatic congestive heart failure,Unstable angina,Arrhythmia with treatment. Patients With a history of myocardial infarction within one year prior to registration. (12)In patients with persistent diarrhea. (There is a watery stool more than three times a day at the time of registration) (13) Patients with previous histories of drug allergy (14)history of drug induced interstitial pneumonia (15)regnant or lactating women or those who declined contraception (16)those judged to be not suitable by the attending physician >postoperative therapy (1) It is found that you have been registered in violation of the selection criteria or exclusion criteria (2) Apparent worsening of the disease due to cancer was observed
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment completion rate of the protocol Treatment
- Secondary Outcome Measures
Name Time Method Response Rate Disease Free Survival Overall Survival Rate of Serious adverse events